Laboratory Co. of America (NYSE:LH - Get Free Report) released its earnings results on Tuesday. The medical research company reported $3.84 earnings per share for the quarter, topping analysts' consensus estimates of $3.73 by $0.11, Zacks reports. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The firm had revenue of $3.35 billion during the quarter, compared to the consensus estimate of $3.41 billion. During the same period in the prior year, the firm posted $3.68 earnings per share. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. Laboratory Co. of America updated its FY 2025 guidance to 15.700-16.400 EPS.
Laboratory Co. of America Stock Up 2.7 %
Shares of NYSE LH traded up $6.61 during mid-day trading on Friday, reaching $247.89. 854,928 shares of the company traded hands, compared to its average volume of 638,815. The company's fifty day moving average is $234.39 and its two-hundred day moving average is $235.62. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.30 and a current ratio of 1.44. Laboratory Co. of America has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The stock has a market cap of $20.74 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 1.71 and a beta of 0.82.
Laboratory Co. of America Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.16%. Laboratory Co. of America's dividend payout ratio is currently 33.29%.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on LH. Truist Financial dropped their price target on Laboratory Co. of America from $285.00 to $274.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Piper Sandler upped their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Robert W. Baird lifted their price target on Laboratory Co. of America from $253.00 to $267.00 and gave the stock an "outperform" rating in a research note on Wednesday. Redburn Atlantic began coverage on shares of Laboratory Co. of America in a research note on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price objective for the company. Finally, Evercore ISI raised shares of Laboratory Co. of America from an "in-line" rating to an "outperform" rating and lifted their target price for the stock from $260.00 to $265.00 in a research report on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $267.85.
Check Out Our Latest Stock Analysis on Laboratory Co. of America
Insider Buying and Selling
In related news, EVP Amy B. Summy sold 758 shares of the company's stock in a transaction on Friday, March 28th. The shares were sold at an average price of $231.67, for a total transaction of $175,605.86. Following the completion of the transaction, the executive vice president now directly owns 5,302 shares in the company, valued at $1,228,314.34. This represents a 12.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam H. Schechter sold 6,121 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares in the company, valued at $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,258 shares of company stock worth $3,518,177. 0.84% of the stock is currently owned by insiders.
Institutional Trading of Laboratory Co. of America
An institutional investor recently bought a new position in Laboratory Co. of America stock. Brighton Jones LLC bought a new stake in Laboratory Co. of America Holdings (NYSE:LH - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,321 shares of the medical research company's stock, valued at approximately $991,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.
Laboratory Co. of America Company Profile
(
Get Free Report)
Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Recommended Stories
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
